Combine supplements of OptiVERO Serum Free Media (SFM). Prepare complementary reagents. Wash cells to remove traces of donor serum. Remove cells from growth surface. Wash and collect cells. Centrifuge. Resuspend. Count. Seed in OptiVERO SFM.
Posted By Annie Cunningham on 2/27/19 2:02 PM
Universal Vaccine Against Seasonal Influenza Steps Closer to Reality with the Results of FluGen Phase 2 Clinical Trial
Posted By Jeanne McAdara Ph.D. on 2/19/19 10:00 AM
On Tuesday, the vaccine company FluGen announced promising preliminary results from a placebo-controlled, Phase 2 clinical trial of their investigational intranasal influenza vaccine, M2SR, in 99 healthy adults challenged with the A/Belgium/4217/2015, H3N2 strain.
Posted By Annie Cunningham on 2/18/19 8:41 AM
Combine supplements of OptiPEAK T Lymphocyte media. Isolate human T lymphocytes from whole blood. Wash to remove traces of donor serum. Activate and expand T lymphocytes (7-10 days) in OptiPEAK T Lymphocyte serum free media. Harvest T lymphocytes. Perform post-expansion, flow cytometric analysis of phenotypic surface markers.
Posted By Randy Alfano Ph.D. on 2/4/19 8:36 AM
In January, there's no better place to be than Miami, FL. While we were excited to escape the cold winter, it was all business for InVitria during Phacilitate 2019 and the Regenerative Medicine Foundation’s World Stem Cell Summit. This year, there was an excitement in the air due to the significant increase in the number of cell therapies in the clinical pipeline. With some cell therapies already being approved, many product innovators at the conference were beginning to focus toward commercial scale-up, bringing new learnings and innovations to the industry. Overall, this event was a big success for our cell culture media team since it was packed with great content, speakers and many partnering meetings.